Skip to main content
Fig. 8 | Biomaterials Research

Fig. 8

From: Controlled release of Clenbuterol from a hydroxyapatite carrier for the treatment of Alzheimer’s Disease

Fig. 8

Histological staining of brain sections shows that CLB activates the signaling pathway in the hippocampus of AD rats (A) Hematoxylin and eosin (H&E) staining. (B) Immunohistochemical staining for BACE-1 and 6E10 (amyloid plaques). Scale bars: 30 μm. (C) Western blotting for synapsin-1, synaptophysin, BACE1, and TNF-α. (D) Quantitative analysis of synapsin-1, synaptophysin, BACE1, and TNF-α expression levels. The relative expression levels were normalized against those of β-actin and presented as the ratios of the values in the experimental group to those in the control group (n = 3, *P < 0.05, **P < 0.01 vs. control; #P < 0.05, ##P < 0.01 vs. AlCl3).

Back to article page